Interpretation
PULMONARY SARCOIDOSIS
In patients with pulmonary sarcoidosis, efzofitimod was safe and well tolerated. Exploratory analyses suggest clinically meaningful improvements after 5 mg/kg efzofitimod with corticosteroid use and improvements in lung function and PROs compared with placebo, without increasing the risk of side effects. However, because of the limited number of patients enrolled in this trial, these findings should be considered only as hypothesis generating. These results support further evaluation in prospective trials of efzofitimod in patients with pulmonary sarcoidosis.